Anti-IL-33 (Human) mAb
Code | Size | Price |
---|
MBL-M138-3 | 100 ug | £350.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: 5H1
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunoprecipitation (IP)
- Western Blot (WB)
Shipping:
4°C
Storage:
-20°C
Images
Documents
Further Information
Applications:
WB - 1 ug/mL (chemiluminescence detection system) IP - 5 ug/100 ng of recombinant protein
Background:
Interleukin-1 (IL-1) family, such as IL-1α/β and IL-18, have important functions in host defense, immune regulation, and inflammation. IL-33, a member of the IL-1 family, that shows to induce T helper (Th) type 2 responses by signaling through the IL-1 receptor-related protein ST2 (IL-1R4), an orphan member of the IL-1 receptor family. Similarly to IL-1α/β and IL-18, IL-33 is synthesized as a 31 kDa precursor protein has been shown to be cleaved by caspase-1 in vitro. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs. IL-33 has been originally identified as NF-HEV, which is a nuclear factor preferentially expressed in high endothelial venules. IL-33 may function as both a proinflammatory cytokine and an intracellular nuclear factor involved in transcriptional regulation.
Concentration:
1 mg/mL
Formulation:
100 ug IgG in 100 ul volume of PBS containing 50% glycerol, pH 7.2. No preservative is contained.
Gene IDs:
Human: 90865 Mouse: 77125
Immunogen Translated:
Full-length recombinant human IL-33 (270 a.a.)
Reactivity:
This antibody reacts with human IL-33
on Western blotting and Immunoprecipitation.
Shelf Life:
1 year
Source:
This antibody was purified from hybridoma
(clone 5H1) supernatant using protein A agarose. This
hybridoma was established by fusion of mouse myeloma
cell P3U1 with Balb/c mouse lymphocyte immunized with
the recombinant full-length human IL-33 (270 aa).
Target:
IL-33
References
1) Hayakawa, H., et al., J. Biol. Chem. 282, 26369-26380 (2007)
2) Carriere, V., et al., PNAS 104, 282-287 (2007)
3) Sanada, S., et al., J. Clin. Invest. 117, 1538-1549 (2007)
4) Schmitz, J., et al., Immunity 23, 479-490 (2005)
5) Dinarello, C. A., Immunity 23, 461-462 (2005)
6) Baekkevold, E. S., et al., Am. J. Pathol. 163, 69-79 (2003)